When will pharma appreciate that investment in diagnostics boosts therapy ROI? | Diaceutics

When will pharma appreciate that investment in diagnostics boosts therapy ROI?

May 4th, 2017

The FT US Healthcare and Life Sciences Summit in New York, now in its sixth successful year, will bring together industry leaders from across the healthcare and life sciences continuum to explore the major transformations ahead. Peter Keeling, CEO of Diaceutics, will be speaking at the May 2017 event on Leveraging diagnostics and analytics (Dx) to boost therapy return on investment – a 360° review.

With over $200bn of drug revenue already shaped by diagnostics and 70 per cent of future pipelines biomarker enabled, the dependence of the future pharma business model on integrating diagnostics is no longer in question. However, this throws into sharp focus the readiness of the industry to understand and optimize the clinical diagnostic ecosystem underpinning every therapy launch.

The question is no longer “Which patients tested positive for a targeted therapy choice?” but rather “How many of the right patients were not tested and missed the treatment opportunity?”

It’s a subject that has long been a concern for Diaceutics, and we have regularly assessed the introduction of diagnostics earlier in the patient journey with the underlying message that not only will more patients get directed to the right treatment but that financial returns will be significantly boosted by such diagnostic investment. In one of our regular Expert Insights, Diagnostics are a Driver, Not a Cost, Keeling uses the example of how Merck invested in a genetic test for KRAS mutations performed on cancer tissue before starting treatment, in order to support its targeted therapy, Erbitux, and direct more patients to the drug.

It’s not only the initial investment in diagnostics that could prove rewarding for patients and pharma alike. With its global network of laboratories and its position as a leading provider of lab analytics and tracking, Diaceutics is perfectly placed to see where testing can be optimized in that setting. In an Expert Insight on data-powered decision-making in personalized medicine, we discuss how with CML, inter-laboratory variation in BCR-ABL1 to control gene ratios is widely recognized. We then ask, “How many patients are NOT tested consistently in the same lab?”, and are able to calculate ‘the potential financial values to companies in the TKI space of proactively reducing inter-laboratory variability in a chronic cancer’. The costs are modest but the financial benefits are significant.

So the theme, enhanced by our latest data and understanding of the diagnostic space, is developed at the FT Summit. The briefing will quantify the missed treatment opportunity based on real-time, real world US testing data, and discuss the readiness of the Pharma industry to radically improve patient testing in support of improving outcomes and accessing higher return on precision medicine investments.

 

Webinars & Podcasts

July 5th, 2019
Liquid Biopsy in NSCLC
August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Publications

June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications